Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Gains from Investment Securities (2019 - 2025)

Historic Gains from Investment Securities for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to $315394.0.

  • Cyclerion Therapeutics' Gains from Investment Securities rose 38522.15% to $315394.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $315394.0, marking a year-over-year increase of 38522.15%. This contributed to the annual value of $7500.0 for FY2023, which is N/A changed from last year.
  • Per Cyclerion Therapeutics' latest filing, its Gains from Investment Securities stood at $315394.0 for Q3 2025, which was up 38522.15% from $314637.0 recorded in Q2 2025.
  • Cyclerion Therapeutics' 5-year Gains from Investment Securities high stood at $450000.0 for Q1 2021, and its period low was -$92000.0 during Q4 2022.
  • In the last 5 years, Cyclerion Therapeutics' Gains from Investment Securities had a median value of $315394.0 in 2025 and averaged $246056.8.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first tumbled by 9700.0% in 2023, then soared by 47777.78% in 2024.
  • Quarter analysis of 5 years shows Cyclerion Therapeutics' Gains from Investment Securities stood at $450000.0 in 2021, then tumbled by 120.44% to -$92000.0 in 2022, then soared by 112.23% to $11250.0 in 2023, then skyrocketed by 477.78% to $65000.0 in 2024, then soared by 385.22% to $315394.0 in 2025.
  • Its Gains from Investment Securities was $315394.0 in Q3 2025, compared to $314637.0 in Q2 2025 and $329458.0 in Q1 2025.